Effects of different preproendothelin-1 mRNA anti-sense oligodeoxynucleotides on ischemic arrhythmias in rats

Journal of Cardiovascular Pharmacology
Li Lin, Wen-Jun Yuan

Abstract

The effects of four anti-sense oligodeoxynucleotides (AS-ODNs) against rat or human preproendothelin-1 mRNA on ischemic arrhythmias in anesthetized rats were studied. AS-ODN (60 nmol/kg) or control (normal saline; sense-ODN, and scrambled-ODN, 60 nmol/kg) was injected 2 h before acute myocardial ischemia elicited by the occlusion of the left anterior descending coronary artery. Arrhythmias during 60-min ischemia were assessed, and plasma endothelin-1 was determined with an endothelin-1-specific radioimmunoassay system. The results showed that anti-senses against human preproendothelin-1 mRNA were anti-arrhythmic without significant impact on hemodynamics, whereas two against rat preproendothelin-1 mRNA and the three controls failed to be anti-arrhythmic. In human antisense groups, both the incidence of reversible ventricular fibrillation and the mortality were decreased to zero. The incidences of ventricular tachycardia and salvos were significantly decreased from almost 100% in the controls to < or =30% (p < 0.01), the arrhythmia score from an average of approximately 3.6 to 0 and 0.7, respectively (p < 0.01 versus controls), and the total ventricular ectopic beats from an average of 307-338 to < 40 (p < 0.01). The human AS-OD...Continue Reading

References

Nov 30, 1990·Biochemical and Biophysical Research Communications·R YorikaneH Koike
Sep 1, 1990·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·M S Simonson, M J Dunn
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A InoueT Masaki
Nov 1, 1983·Canadian Journal of Physiology and Pharmacology·K M JohnstonM J Walker
Jan 1, 1995·Clinical Pharmacokinetics·S AgrawalJ Tang
Aug 1, 1993·Cardiovascular Research·T TønnessenG Christensen
Jan 1, 1996·Journal of Cardiovascular Pharmacology·S KobayashiY Masuda
Jul 1, 1997·Clinical and Experimental Hypertension : CHE·P SinnayahJ P Coghlan
May 20, 1998·Nature Biotechnology·E M Greetham
Dec 23, 1998·Cardiovascular Research·I SharifC L Wainwright

❮ Previous
Next ❯

Citations

Nov 29, 2011·Apoptosis : an International Journal on Programmed Cell Death·Ji FangLi Lin
May 10, 2012·FEBS Letters·Dong LiAn-Jing Ren

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.